N,N-diethyl-2-carboxaldehyde-6-trifluoromethylbenzamide | 850038-82-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N,N-diethyl-2-carboxaldehyde-6-trifluoromethylbenzamide
• 英文别名: N,N-diethyl-2-formyl-6-(trifluoromethyl)benzamide
• CAS: 850038-82-3
• 化学式: C₁₃H₁₄F₃NO₂
• 分子量: 273.255
• InChiKey: YOUNQYCMVSGBSO-UHFFFAOYSA-N

物化性质

• 沸点：
  376.1±42.0 °C(Predicted)
• 密度：
  1.225±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  37.4
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N,N-diethyl-2-carboxaldehyde-6-trifluoromethylbenzamide 在 palladium on activated charcoal 盐酸 、 N-溴代丁二酰亚胺(NBS) 、 硫酸 、 氢气 、 sodium acetate 、 溶剂黄146 作用下， 以 乙醚 、 乙醇 、 二氯甲烷 为溶剂， 100.0 ℃ 、551.58 kPa 条件下， 反应 141.0h， 生成 N-(tert-butoxycarbonyl)-(R)-9-bromo-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one
  参考文献：
  名称：

  Discovery of (R)-9-Ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a Selective, Orally Active Agonist of the 5-HT_2C Receptor

  摘要：

  Robust pharmaceutical treatment of obesity has been limited by the undesirable side-effect profile of currently marketed therapies. This paper describes the synthesis and optimization of a new class of pyrazinoisoindolone-containing, selective 5-HT2C agonists as antiobesity agents. Key to optimization of the pyrazinoisoindolone core was the identification of the appropriate substitution pattern and functional groups which led to the discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one (58), a 5-HT2C agonist with > 300-fold functional selectivity over 5-HT2B and > 70-fold functional selectivity over 5-HT2A. Oral dosing of 58 reduced food intake in an acute rat feeding model, which could be completely reversed by a selective 5-HT2C antagonist and caused a reduction in body weight gain in a 4-day rat model.

  DOI：

  10.1021/jm0612968
• 作为产物：
  描述：

  2-三氟甲基苯甲酰氯 在 四甲基乙二胺 、 仲丁基锂 作用下， 以 四氢呋喃 、 正己烷 、 二氯甲烷 为溶剂， 反应 17.5h， 生成 N,N-diethyl-2-carboxaldehyde-6-trifluoromethylbenzamide
  参考文献：
  名称：

  Discovery of (R)-9-Ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a Selective, Orally Active Agonist of the 5-HT_2C Receptor

  摘要：

  Robust pharmaceutical treatment of obesity has been limited by the undesirable side-effect profile of currently marketed therapies. This paper describes the synthesis and optimization of a new class of pyrazinoisoindolone-containing, selective 5-HT2C agonists as antiobesity agents. Key to optimization of the pyrazinoisoindolone core was the identification of the appropriate substitution pattern and functional groups which led to the discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one (58), a 5-HT2C agonist with > 300-fold functional selectivity over 5-HT2B and > 70-fold functional selectivity over 5-HT2A. Oral dosing of 58 reduced food intake in an acute rat feeding model, which could be completely reversed by a selective 5-HT2C antagonist and caused a reduction in body weight gain in a 4-day rat model.

  DOI：

  10.1021/jm0612968

文献信息

• Discovery of (<i>R</i>)-9-Ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-<i>a</i>]isoindol- 6(2<i>H</i>)-one, a Selective, Orally Active Agonist of the 5-HT_2C Receptor
  作者：Dean A. Wacker、Jeffrey G. Varnes、Sarah E. Malmstrom、Xueying Cao、Chen-Pin Hung、Thao Ung、Ginger Wu、Ge Zhang、Eva Zuvich、Michael A. Thomas、William J. Keim、Mary Jane Cullen、Kenneth W. Rohrbach、Qinling Qu、Rangaraj Narayanan、Karen Rossi、Evan Janovitz、Lois Lehman-McKeeman、Mary F. Malley、James Devenny、Mary Ann Pelleymounter、Keith J. Miller、Jeffrey A. Robl

  DOI：10.1021/jm0612968

  日期：2007.3.1

  Robust pharmaceutical treatment of obesity has been limited by the undesirable side-effect profile of currently marketed therapies. This paper describes the synthesis and optimization of a new class of pyrazinoisoindolone-containing, selective 5-HT2C agonists as antiobesity agents. Key to optimization of the pyrazinoisoindolone core was the identification of the appropriate substitution pattern and functional groups which led to the discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one (58), a 5-HT2C agonist with > 300-fold functional selectivity over 5-HT2B and > 70-fold functional selectivity over 5-HT2A. Oral dosing of 58 reduced food intake in an acute rat feeding model, which could be completely reversed by a selective 5-HT2C antagonist and caused a reduction in body weight gain in a 4-day rat model.
• Synthesis and SAR of 2,3,3a,4-tetrahydro-1H-pyrrolo[3,4-c]isoquinolin-5(9bH)-ones as 5-HT2C receptor agonists
  作者：John M. Fevig、Jianxin Feng、Karen A. Rossi、Keith J. Miller、Ginger Wu、Chen-Pin Hung、Thao Ung、Sarah E. Malmstrom、Ge Zhang、William J. Keim、Mary Jane Cullen、Kenneth W. Rohrbach、Qinling Qu、Jinping Gan、Mary Ann Pelleymounter、Jeffrey A. Robl

  DOI：10.1016/j.bmcl.2012.10.091

  日期：2013.1

  A series of 2,3,3a,4-tetrahydro-1H-pyrrolo[3,4-c]isoquinolin-5(9bH)-ones is described, several examples of which exhibit potent 5-HT2C agonism with excellent selectivity over the closely related 5-HT2A and 5-HT2B receptors. Compounds such as 38 and 44 were shown to be effective in reducing food intake in an acute rat feeding model. (C) 2012 Elsevier Ltd. All rights reserved.